Evidence map›Paper›PMID 42441716›Full record

ArticlePLoS pathogens2026

Structural requirements of blood factors binding to soluble hexon trimers with implications for adenovirus cell targeting and immune evasion.

Olivia X Ma, Shao-Chia Lu, Haley E Mudrick, Mary E Barry, Jarrod B French, Michael A Barry, Vijay S Reddy

Abstract read
In one paragraph

Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Olivia X MaThe Hormel Institute, University of Minnesota, Austin, Minnesota, United States of America.
Shao-Chia LuDepartment of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, United States of America.
Haley E MudrickMolecular Pharmacology and Experimental Therapeutics Graduate Program, Mayo Clinic, Rochester, Minnesota, United States of America.
Mary E BarryDepartment of Immunology, Department of Molecular Medicine, Mayo Clinic, Rochester, Minnesota, United States of America.
Jarrod B FrenchThe Hormel Institute, University of Minnesota, Austin, Minnesota, United States of America.
Michael A BarryDepartment of Internal Medicine, Division of Infectious Diseases, Mayo Clinic, Rochester, Minnesota, United States of America.
Vijay S ReddyThe Hormel Institute, University of Minnesota, Austin, Minnesota, United States of America.ORCID 0000-0003-4638-8277

Funding

Shielding Replicating Single-cycle Vaccines against SARS-CoV-2R56AI161367 · NIAID · MAYO CLINIC ROCHESTER · PI BARRY, MICHAEL A · 2023 to 2023
$471k
NIAID NIH HHS R56 AI161367
6 · The paper itself

Abstract

Human adenovirus serotype 5 (HAdV-C5) is widely used as a gene delivery vector in both experimental and clinical settings. Upon intravenous administration, HAdV-C5 exhibits strong liver tropism, largely mediated by interactions between its major capsid protein, hexon (Hx), and coagulation factor X (FX). In contrast, the closely related species C adenovirus 6 (HAdV-C6) also targets the liver but shows reduced dependency on coagulation factors, whereas species D adenovirus 26 (HAdV-D26) does not bind coagulation factors altogether. To define the structural basis of this serotype-specific host factor recognition, we determined high-resolution cryo-electron microscopy structures of isolated hexon trimers from HAdV-C5 and HAdV-C6 in complex with coagulation factors FX and prothrombin (factor II, FII). The resulting atomic models reveal conserved binding interfaces involving the γ-carboxyglutamic acid (Gla) domains of both coagulation factors and the hypervariable regions HVR5 and HVR7 lining the surface cavities of HAdV-C5 and HAdV-C6 hexons. Structures of hexon complexes formed by co-incubation with both FX and FII further reveal serotype-specific binding preferences under physiologically relevant conditions, showing that HAdV-C5 hexon preferentially engages FX, whereas HAdV-C6 hexon favors FII. By contrast, HAdV-D26 hexon does not bind either factor, likely due to an insertion constrained by proline residues in the HVR5 loop that restricts the factor access to the hexon cavity. Together, these findings provide a detailed structural framework for adenovirus-coagulation factor interactions and support the rational engineering of adenovirus vectors with improved targeting and safety profiles.

Indexed as

Adenoviruses, HumanBlood Coagulation FactorsCapsid ProteinsCryoelectron MicroscopyFactor XHumansProtein BindingBlood Coagulation FactorsCapsid ProteinsFactor Xhexon capsid protein, Adenovirus

Identifiers

PMID42441716
PMCPMC13379079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.